- Company
- AZ supplies 20 million doses of COVID-19 vaccines to Korea
- by Dec 10, 2020 06:09am
- The government announced a contract with AstraZeneca and other COVID-19 vaccine developers on the 8th, and AstraZeneca Korea said, "We are pleased to be able to supply (vaccine) for the public benefit." Korea AstraZeneca (CEO, Sang-pyo Kim) said on the day, "According to the contract with the KDCA, we will supply 20 million doses of AZD12
- Policy
- Secured COVID-19 vaccines for 44 million people
- by Lee, Tak-Sun Dec 10, 2020 06:09am
- The government announced that it has secured up to COVID-19 vaccines for 44 million people AstraZeneca, a global pharmaceutical company, has already signed a contract to supply 10 million vaccines (20 million doses), and Pfizer and Modena announced that they have signed a binding purchase agreement with 10 million doses (20 million doses) re
- Product
- What’s it like to have ATTR-CM in Korea
- by won, jong-hyuk Dec 10, 2020 06:09am
- A few years ago, a 50-year-old man visited a hospital when he experienced shortness of breath and edema. But he had to visit a number of hospitals for years for examination as he struggled to pin point the name of the disease. And one day, he felt tingling sensation in his toes and examined the heart. That was the time he had to face his rar
- InterView
- “PARP inhibitor as backbone in ovarian cancer treatment”
- by Eo, Yun-Ho Dec 9, 2020 10:54am
- Disease with limited treatment options tends to simplify the treatment pattern itself. But an emergence of a new treatment mechanism can open doors to various treatment strategies. A poly ADP-ribose polymerase (PARP) inhibitor is the new mechanism opening the new doors to the ovarian cancer treatment scene. PARP inhibitors that targe
- Policy
- Clinical data for COVID-19 vaccine will be submitted soon
- by Lee, Tak-Sun Dec 9, 2020 05:56am
- Minister of Health and Welfare Park Neung-hoo said that AstraZeneca will soon submit clinical trial data for COVID-19 vaccine to the MFDS. On the morning of the 8th, the government announced that it has signed a purchase contract with AstraZeneca for 10 million COVID-19 vaccines. In a press briefing after the announcement, Minister Park s
- Company
- Prolia's sales this year are ₩54.9 billion
- by Kim, Jin-Gu Dec 9, 2020 05:56am
- Amgen's osteoporosis treatment Prolia (Denosumab) is popular in the market after the expansion of benefits. Until the third quarter of this year, it was found that the cumulative sales amount increased by 87% compared to the same period last year. This is in contrast to the decline in sales of major osteoporosis treatments excluding Proli
- Company
- What drugs will their patents expire next year?
- by Kim, Jin-Gu Dec 9, 2020 05:56am
- 155 patents, including Hanmi's Amosartan, will expire next year. The patents of two NOACs (New Oral Anticoagulant), which have grown rapidly in recent years, are also set to expire next year. According to the MFDS on the 4th, there are a total of 155 patents scheduled to expire in 2021. Among these, the item that attracts the most attentio
- Company
- Dong-A ST’s Jublia is growing by 15%
- by Kim, Jin-Gu Dec 9, 2020 05:56am
- Jublia's sales in the market for athlete's foot treatment for nails increased significantly last summer. Sales of Fulcare, which was a leading item in the existing market, decreased by 30% compared to the previous year. It is observed to have decreased by half compared to 5 years ago. According to IQVIA, a drug market research agency on
- Company
- 117 Organon-transferring MSD employees files for a remedy
- by Dec 8, 2020 03:55pm
- 117 employees notified to transfer from MSD Korea to a new subsidiary Organon have requested a remedy for unfair transfer. Resisting against the transfer ordered without consent, the MSD Korea Labor Union filed a remedy for unfair transfer to the Seoul Regional Labor Relations Commission on Dec. 1. The application for the remedy was
- Policy
- Drug price negotiation agreement by NHIS is 97.9%
- by Lee, Hye-Kyung Dec 8, 2020 06:12am
- 285 items (97.9%) completed drug price negotiations. Dailypharm reviewed the current status of drug price negotiations on December 29, 2006, after the last health insurance registration method was switched to the positive list system as part of a plan to optimize drug costs. Negotiations were completed for 1,924 items out of a total of 1972 n
